Windtree Therapeutics (WINT) and XOMA (XOMA) Critical Survey

Windtree Therapeutics (OTCMKTS: WINT) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

0.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of XOMA shares are owned by institutional investors. 0.8% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 3.0% of XOMA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and XOMA, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
XOMA 0 1 2 0 2.67

XOMA has a consensus price target of $35.50, suggesting a potential upside of 3.32%. Given XOMA’s stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Windtree Therapeutics.

Profitability

This table compares Windtree Therapeutics and XOMA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
XOMA -3.51% -1.14% 0.95%

Earnings and Valuation

This table compares Windtree Therapeutics and XOMA’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 180.02 -$39.49 million ($71.83) -0.08
XOMA $5.56 million 50.30 -$53.53 million ($3.26) -10.54

Windtree Therapeutics has higher earnings, but lower revenue than XOMA. XOMA is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Windtree Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, XOMA has a beta of 3.17, suggesting that its share price is 217% more volatile than the S&P 500.

Summary

XOMA beats Windtree Therapeutics on 10 of the 14 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

What are top analysts saying about Windtree Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Windtree Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit